Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of the Safety and Efficacy of SVN53-67/M57-KLH (SurVaxM) in Survivin-Positive Newly Diagnosed Glioblastoma

NCT02455557 is registered in ClinicalTrials.gov with Roswell Park Cancer Institute as lead sponsor.

NCT NCT02455557
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02455557 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of the Safety and Efficacy of SVN53-67/M57-KLH (SurVaxM) in Survivin-Positive Newly Diagnosed Glioblastoma
Lead sponsor
Roswell Park Cancer Institute
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 4, 2015
Completion date
September 2, 2026
Enrollment
66 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma, gliosarcoma